StackTerminal.Health

BETA
Alternative layoutGrade B · 84Clean

Research-only: Recovery + Skin (GLOW-style grouping)

Adds a copper peptide often discussed in cosmetic/skin contexts to a recovery/joint pairing. Evidence is indirect & component-based.

What this is for
General support
recovery, skin, research-only
Why you are seeing this
Goal fit: recovery, skin, research-only.
What to do next
Add body metrics if you want dose previews to reflect your weight rather than the reference dose.
← BackView current layout
Buy stack
Public•Built 06 Feb 2026•3 ingredients•No interactions detected
Core stack
The main ingredients doing the work.
3 key items
BPC-157Low
PLACEHOLDER • Lyophilized •
Preclinical repair signals; limited human evidence.
Buy ingredient →
1mg
Safety / pharmacokinetics
Low
Population: Healthy volunteers
Study type: Registered phase 1 trial (results not posted)
Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284
Musculoskeletal healing (preclinical)
Low
Population: Animal injury models (multiple tissues)
Study type: Narrative review of preclinical evidence
Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/
Soft tissue healing signals (preclinical)
Low
Population: Animal models (multiple tissues)
Study type: Review (preclinical-focused)
Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/
TB500 (TB4 / Thymosin Beta-4)Low
PLACEHOLDER • Lyophilized •
Preclinical wound-healing biology; athlete outcomes uncertain.
Buy ingredient →
1mg
Wound healing
Low
Population: Rat full-thickness wound model
Study type: Preclinical animal study
Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/
Wound healing (clinical development)
Low
Population: Patients with venous stasis ulcers
Study type: Registered phase 2 trial (TB4 gel)
Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091
Wound healing (reviewed clinical context)
Low
Population: Stasis and pressure ulcer clinical programs
Study type: Review article
Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/
GHK-CuLow
PLACEHOLDER • Other •
Mixed cosmetic/derm evidence; formulation-dependent.
Buy ingredient →
1mg
Extracellular matrix remodeling via MMP-2 upregulation
Low
Population: In vitro (human fibroblast cultures)
Study type: In vitro mechanistic study
Dose context: — • Duration: Cell culture (acute exposure)

GHK-Cu significantly increased MMP-2 (matrix metalloproteinase-2) protein levels and corresponding mRNA in fibroblast culture media. TIMP-1 and TIMP-2 secretion also rose, indicating balanced matrix remodeling activity. The copper component was essential - GHK peptide alone produced no effect. Authors conclude GHK-Cu acts as both an activator of connective tissue production and a regulator of extracellular matrix remodeling.

Citation: Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci. 2000;67(18):2257-65.•DOI: 10.1016/s0024-3205(00)00803-1•https://pubmed.ncbi.nlm.nih.gov/11045606/
Grade is LOW because this is an in vitro study only - no human or animal data. Results are mechanistically plausible and consistent with GHK-Cu's known biology, but cannot be directly extrapolated to dosing or clinical outcomes.
Skin appearance / remodeling (summary of clinical + mechanistic evidence)
Moderate
Population: Humans (cosmetic/dermatologic contexts) + preclinical
Study type: Review
Dose context: —

Review summarizes reported improvements in some skin measures & broad tissue-remodeling biology; quality & comparators vary widely. The authors note a surprising absence of rigorous modern clinical trials for GHK-Cu in anti-wrinkle applications despite widespread cosmetic use.

Citation: Pickart et al., Molecules (2018) — Regenerative and Protective Actions of the GHK-Cu Peptide•DOI: 10.3390/ijms19071987•https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
Wrinkle improvement (objective measures)
Low
Population: Adults using topical copper tripeptide complex
Study type: Clinical study (objective evaluation)
Dose context: —

One objective evaluation reported no significant improvement in wrinkles/overall skin quality, though patient satisfaction differed; underscores mixed results across formulations & endpoints.

Citation: Miller et al., Arch Facial Plast Surg (2006) — Topical copper tripeptide complex evaluation•DOI: 10.1001/archfaci.8.4.252•https://www.liebertpub.com/abs/doi/10.1001/archfaci.8.4.252
Stack pre-check
No personal data connected — connect wearables or upload bloodwork for a personalised check
Clean
Supplements
3
Training load
Unknown
No flags
No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis
Pharmacokinetic + pair-level checks
Timing optimizations
BPC-157
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
TB500 (TB4 / Thymosin Beta-4)
Take ~1h before the intended effect window
Reaches peak plasma concentration in ~1h. Half-life ~4h.
GHK-Cu
Take ~15 min before the intended effect window
Reaches peak plasma concentration in ~15 min. Half-life ~0.5h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Similar community stacks

If this is close but not quite right, start from a similar stack rather than from zero.

Browse all community stacks →
recoveryjointsresearch-only

Research-only: Recovery / Joints (BPC-157 + TB4)

by@athlete

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.

BPC-157
1mg
TB500 (TB4 / Thymosin Beta-4)
1mg
New
View
gutdigestionresearch-only

Research-only: Gut / Inflammation (KPV + BPC-157)

by@athlete

Groups gut-inflammation oriented peptides (mostly studied in preclinical colitis/inflammation models).

KPV
1mg
BPC-157
1mg
Magnesium (Glycinate)
400mg
New
View
sleepcalmfocus

Research-only: Calm + Focus (Selank + Semax)

by@athlete

Non-stimulant cognitive/calm pairing commonly discussed in nootropic communities.

Selank
1mg
Semax
10mg
New
View